Aurobindo Pharma Share Price: Share price of Aurobindo Pharma falls as Sensex drops 326.34 points
Did you Know? Stock score of Aurobindo Pharma Ltd moved down by 1 in a week on a 10-point scale. View Latest Stock Report »
The share price ofLtd. dropped 5.08 per cent to Rs 685.25 at 01:52PM (IST) in Friday’s trade. The scrip has hit a high of Rs 722.0 and low of Rs 685.2 so far during the session. The stock had closed at Rs 721.9 in the previous session.The counter has had a total traded volume of 424834 shares so far with a value of Rs 29.78 crore on the NSE . It traded at a price-to-earnings multiple of 7.56 and a price-to-book ratio of 2.36.A higher P/E ratio shows investors are willing to pay a higher price for per rupee earnings given by the stock because of better future growth expectations.The price-to-book value indicates the inherent value of a company and reflects the price investors are willing to pay even for no growth in the business.The scrip declined 20.07 per cent during the past one year, while the 30-share index advanced 46.02 per cent during the same period.Aurobindo Pharma Ltd. belongs to the Pharma - Indian industry.Promoters held 48.76 per cent stake in the company as of 30-Jun-2021, while foreign investors and domestic institutional investors ownership stood at 23.7 per cent and 9.03 per cent, respectively.The company reported consolidated net sales of Rs 5783.29 crore for the quarter ended 30-Jun-2021, down 4.87 per cent from the previous quarter’s Rs 6079.6 crore and down 4.26 per cent from the year-ago quarter’s Rs 6040.37 crore.Profit for the latest quarter stood at Rs 769.97 crore, down 1.36 per cent from the same quarter a year ago.
Aurobindo Pharma share price: Buy Aurobindo Pharma, target price Rs 900: Motilal Oswal
Did you Know? Stock score of Aurobindo Pharma Ltd moved down by 1 in a week on a 10-point scale. View Latest Stock Report »
Motilal Oswal has buy call onwith a target price of Rs 900. The current market price of Aurobindo Pharma is Rs 751.1. Time period given by analyst is one year when Aurobindo Pharma Ltd. price can reach defined target.Aurobindo Pharma Ltd., incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 44607.51 Crore) operating in Pharmaceuticals sector.For the quarter ended 30-06-2021, the company reported a Consolidated Total Income of Rs 5783.29 Crore, down -4.87 % from last quarter Total Income of Rs 6079.60 Crore and down -4.26 % from last year same quarter Total Income of Rs 6040.37 Crore. Company reported net profit after tax of Rs 778.97 Crore in latest quarter.The brokerage values ARBP at 14x its 12-month forward earnings to arrive at TP of INR900. ARBP’s efforts are underway a) to enhance product offerings comprising Oncology, Hormones, Depot Injections, Inhalers, Biosimilars, Topicals, and Patches, and b) improving margin in the EU business.Promoters held 51.8 per cent stake in the company as of June 30, 2021, while FIIs held 23.7 per cent, DIIs 14.7 per cent and public and others 9.8 per cent.
Aurobindo Pharma hits 52-week low, slips 25% in one month
Shares of hit a fresh 52-week low of Rs 728.50 as they fell 3.4 per cent on the BSE in intra-day trade on Tuesday. The stock of the pharmaceutical company has declined 12 per cent in the past three trading days after the company reported a disappointing operational performance in the June 2021 quarter (Q1FY22), amid a decline across the US market and antiretroviral (ARVs). The stock of the pharmaceutical company was trading at its lowest level since June 2020. In the past one month, it has lost 25 per cent, as compared to a 4.4 per cent rise in the S&P BSE Sensex.
In Q1FY22, the company’s profit after tax (PAT) was down 1.7 per cent year-on-year (YoY) and 4 per cent quarter-on-quarter (QoQ) at Rs 770 crore. It was, however, in line with analysts' estimate on higher than expected other income and a lower tax rate. Revenue, meanwhile, de-grew 3.8 per cent YoY and 5 per cent QoQ to Rs 5,702 crore.
US revenue in Q1FY22 declined by 1.5 per cent YoY to Rs 2,681 crore, accounting for 47 per cent of consolidated revenue. ARV business revenue for the quarter was at Rs 296 crore, down 30.3 per cent YoY, and accounted for 5.1 per cent of total revenue. Ebitda (earnings before interest, taxes, depreciation, and amortization) margins remained flat at 21.2 per cent.
Separately, said the company has entered into definitive agreements under which the company will subscribe to fresh equity shares in Cronus Pharma Specialities India Private Limited (Cronus) amounting to Rs 420 crore.
Cronus is a Hyderabad based generic veterinary pharmaceutical products company engaged in the development, manufacturing and sale of veterinary pharmaceutical products. Subsequent to this investment, the company will own 51 per cent of the equity share capital of Cronus, said.
“The price erosion in the US was in high single-digit, but this would normalise, going forward (H2FY22). Aurobindo’s US pipeline provides good growth visibility with assets across injectables, biosimilars, vaccines and OTC products,” analysts at HDFC Securities said in the result update.
Its recent acquisition of Cronus Pharma (animal health business) and OTC/brands in the US are expected to accelerate growth, the brokerage said, adding that the potential value unlocking of the injectables business (disclosure in Q2FY22) and resolution of US FDA facilities are the key near-term triggers.
“On the regulatory front, while a few other plants still remain under the USFDA scrutiny, the erstwhile clearance of a critical plant (Unit IV) indicates that the company continues to work towards stricter adherence. That said, the US generics scenario is anything but encouraging at the current juncture due to persistent base business price erosion and slower injectables ramp-up,” analysts at ICICI Securities said.